These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 32204344

  • 1. Immunotherapy Strategies for the Prevention and Treatment of Distinct Stages of Type 1 Diabetes: An Overview.
    Rapini N, Schiaffini R, Fierabracci A.
    Int J Mol Sci; 2020 Mar 19; 21(6):. PubMed ID: 32204344
    [Abstract] [Full Text] [Related]

  • 2. Diabetes technology and treatments in the paediatric age group.
    Shalitin S, Peter Chase H.
    Int J Clin Pract Suppl; 2011 Feb 19; (170):76-82. PubMed ID: 21323816
    [Abstract] [Full Text] [Related]

  • 3. Insulin during pregnancy, labour and delivery.
    de Valk HW, Visser GH.
    Best Pract Res Clin Obstet Gynaecol; 2011 Feb 19; 25(1):65-76. PubMed ID: 21186142
    [Abstract] [Full Text] [Related]

  • 4. Insulin secretion measured by stimulated C-peptide in long-established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study.
    McGee P, Steffes M, Nowicki M, Bayless M, Gubitosi-Klug R, Cleary P, Lachin J, Palmer J, DCCT/EDIC Research Group.
    Diabet Med; 2014 Oct 19; 31(10):1264-8. PubMed ID: 24836354
    [Abstract] [Full Text] [Related]

  • 5. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
    Rother KI, Spain LM, Wesley RA, Digon BJ, Baron A, Chen K, Nelson P, Dosch HM, Palmer JP, Brooks-Worrell B, Ring M, Harlan DM.
    Diabetes Care; 2009 Dec 19; 32(12):2251-7. PubMed ID: 19808924
    [Abstract] [Full Text] [Related]

  • 6. Optimal glycemic control with insulin therapy: lowering A1C and raising standards.
    Braunstein SN, Combs P, Campbell RK.
    Diabetes Educ; 2003 Dec 19; Suppl():1-15. PubMed ID: 15055169
    [No Abstract] [Full Text] [Related]

  • 7. Role of emerging new technologies.
    Garg SK.
    Diabetes Technol Ther; 2008 Oct 19; 10(5):413-4. PubMed ID: 18715219
    [No Abstract] [Full Text] [Related]

  • 8. Glucose control in type 1 diabetes: from conventional to intensive therapy.
    Zinman B.
    Clin Cornerstone; 1998 Oct 19; 1(3):29-38. PubMed ID: 10682171
    [Abstract] [Full Text] [Related]

  • 9. From pumps to prevention: recent advances in the treatment of type 1 diabetes.
    Sherr J, Cengiz E, Tamborlane WV.
    Drug Discov Today; 2009 Oct 19; 14(19-20):973-81. PubMed ID: 19580883
    [Abstract] [Full Text] [Related]

  • 10. Autologous stem cell transplantation for early type 1 diabetes mellitus.
    Couri CE, Voltarelli JC.
    Autoimmunity; 2008 Dec 19; 41(8):666-72. PubMed ID: 18958750
    [Abstract] [Full Text] [Related]

  • 11. Novel therapies in the management of type I diabetes mellitus.
    Ludvigsson J.
    Panminerva Med; 2012 Dec 19; 54(4):257-70. PubMed ID: 23123577
    [Abstract] [Full Text] [Related]

  • 12. The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes.
    Chase HP, Lockspeiser T, Peery B, Shepherd M, MacKenzie T, Anderson J, Garg SK.
    Diabetes Care; 2001 Mar 19; 24(3):430-4. PubMed ID: 11289463
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Update on global intervention studies in type 1 diabetes.
    Chiang JL, Haller MJ, Schatz DA.
    Endocrinol Metab Clin North Am; 2012 Dec 19; 41(4):695-712. PubMed ID: 23099265
    [Abstract] [Full Text] [Related]

  • 15. Liberal Glycemic Control in Critically Ill Patients With Type 2 Diabetes: An Exploratory Study.
    Kar P, Plummer MP, Bellomo R, Jenkins AJ, Januszewski AS, Chapman MJ, Jones KL, Horowitz M, Deane AM.
    Crit Care Med; 2016 Sep 19; 44(9):1695-703. PubMed ID: 27315191
    [Abstract] [Full Text] [Related]

  • 16. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
    Vinik A.
    Clin Ther; 2007 Jun 19; 29(6 Pt 1):1236-53. PubMed ID: 18036387
    [Abstract] [Full Text] [Related]

  • 17. Defining the role of basal and prandial insulin for optimal glycemic control.
    Horton ES.
    J Am Coll Cardiol; 2009 Feb 03; 53(5 Suppl):S21-7. PubMed ID: 19179213
    [Abstract] [Full Text] [Related]

  • 18. Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes.
    Koga M, Murai J, Saito H, Kasayama S.
    Diabetes Care; 2010 Feb 03; 33(2):270-2. PubMed ID: 19846794
    [Abstract] [Full Text] [Related]

  • 19. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy.
    Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD.
    Diabetes Care; 2008 Oct 03; 31(10):1927-32. PubMed ID: 18556343
    [Abstract] [Full Text] [Related]

  • 20. IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes.
    Diaz-de-Durana Y, Lau J, Knee D, Filippi C, Londei M, McNamara P, Nasoff M, DiDonato M, Glynne R, Herman AE.
    PLoS One; 2013 Oct 03; 8(10):e78483. PubMed ID: 24205242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.